Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00890825
First received: April 29, 2009
Last updated: November 9, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2016
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 22, 2013
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):